English
Bahasa Indonesia
简体中文
繁體中文
Tiếng Việt
Share
CELLAAX MALAYSIA AT THE FOREFRONT OF DISCOVERING POTENTIAL REGENERATIVE POSSIBILITIES IN DENTAL PULP STEM CELLS
- CELLAAX
- April 4, 2022
- Press Release
Kuala Lumpur, 4th April 2022 – CELLAAX Malaysia, a biopharmaceutical company engaged in the research and development of cellular therapy, recently announced its preliminary findings on the possible uses of stem cells derived from dental pulp to treat conditions of the nervous system.
“Mesenchymal stem cells derived from dental pulp tissue possess self-renewal and differentiation potential. They also inherit neuroprotective and neurogenic properties which may promote neuroregeneration, making them a promising candidate for further studies”, said CELLAAX medical writer and researcher Yun Yan Foo during her poster presentation at the Malaysian Tissue Engineering & Regenerative Medicine Scientific Meeting (MTERMS) 2022.
The virtual conference held in March was themed ‘Advancing Tissue Engineering and Regenerative Research Towards Precision Medicine’. Organized by TESMA (the largest tissue engineering and regenerative medicine network in Malaysia), the yearly conference is a homegrown platform for local scientists, researchers and experts within the industry and government to come together in the name of regenerative medicine research and therapy in Malaysia.
“Regenerative medicine is the heart of what we do here at CELLAAX. As a company focused on the research and development of cellular therapy, we want to continue pushing boundaries and leading in new discoveries”, said Angelina Tiah, Chief Scientist at CELLAAX Malaysia.
“We are still in the early stages of evaluating the possibilities of the use of dental pulp to treat brain and nerve conditions, but it is indeed pivotal for neurological diseases such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s or Parkinson’s”, continued Angelina.
Stem cell-based therapies are at the forefront of research in the field of regenerative medicine due to their therapeutic potential in treating various illnesses and defects.
CELLAAX is spearheading various clinical trials alongside their strategic partner 23 Century International Life Science Centre to bring promising breakthroughs in cellular therapy.
*ENDS*